Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study

详细信息    查看全文

• 作者：Daouda Sissoko ; MD^a ; ^b ; ^&dagger ; ; Sophie Duraffour ; PhD^c ; ^d ; ^&dagger ; ; Romy Kerber ; PhD^d ; ^e ; ^&dagger ; ; Jacques Seraphin Kolie ; MD^f ; Abdoul Habib Beavogui ; PhD^f ; Alseny-Modet Camara ; MD^g ; Gé ; raldine Colin ; PharmD^a ; ^h ; Toni Rieger ; PhD^d ; ^e ; Lisa Oestereich ; PhD^d ; ^e ; Bernadett Pá ; lyi ; MScⁱ ; Stephanie Wurr^d ; ^e ; Jeremie Guedj ; PhD^j ; Thi Huyen Tram Nguyen ; PhD^j ; Rosalind M Eggo ; PhD^k ; Conall H Watson ; MFPH^k ; W John Edmunds ; PhD^k ; Joseph Akoi Bore ; MSc^c ; ^l ; Fara Raymond Koundouno ; MSc^c ; ^l ; Mar Cabeza-Cabrerizo ; MSc^c ; ^d ; Lisa L Carter ; PhD^c ; ^m ; Liana Eleni Kafetzopoulou ; MSc^c ; ⁿ ; Eeva Kuisma ; PhD^c ; ^o ; Janine Michel ; PhD^c ; ^p ; Livia Victoria Patrono ; PhD^c ; ^d ; Natasha Y Rickett ; MRes^c ; ^q ; Katrin Singethan ; PhD^c ; ^r ; Martin Rudolf ; PhD^d ; ^e ; Angelika Lander^p ; Elisa Pallasch^d ; ^e ; Sabrina Bockholt^d ; ^e ; Estefaní ; a Rodrí ; guez ; PhD^e ; ^s ; Antonino Di Caro ; MD^c ; ^t ; Roman Wö ; lfel ; MD^c ; ^u ; Martin Gabriel ; MD^c ; ^d ; Cé ; line Gurry^v ; Pierre Formenty ; DVM^v ; Sakoba Keï ; ta ; MD^l ; Denis Malvy ; PhD^a ; ^b ; ^&Dagger ; ; Miles W Carroll ; PhD^c ; ^o ; ^w ; ^&Dagger ; ; Xavier Anglaret ; PhD^a ; ^h ; ^&Dagger ; ; Dr Stephan Gü ; nther ; MD^c ; ^d ; ^e ; ^&Dagger ; ; ^{guenther@bni.uni-hamburg.de}
• 刊名：The Lancet Global Health
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：5
• 期：1
• 页码：e80-e88
• 全文大小：910 K
• 卷排序：5

文摘

By January, 2016, all known transmission chains of the Ebola virus disease (EVD) outbreak in west Africa had been stopped. However, there is concern about persistence of Ebola virus in the reproductive tract of men who have survived EVD. We aimed to use biostatistical modelling to describe the dynamics of Ebola virus RNA load in seminal fluid, including clearance parameters.MethodsIn this longitudinal study, we recruited men who had been discharged from three Ebola treatment units in Guinea between January and July, 2015. Participants provided samples of seminal fluid at follow-up every 3–6 weeks, which we tested for Ebola virus RNA using quantitative real-time RT-PCR. Representative specimens from eight participants were then inoculated into immunodeficient mice to test for infectivity. We used a linear mixed-effect model to analyse the dynamics of virus persistence in seminal fluid over time.FindingsWe enrolled 26 participants and tested 130 seminal fluid specimens; median follow up was 197 days (IQR 187–209 days) after enrolment, which corresponded to 255 days (228–287) after disease onset. Ebola virus RNA was detected in 86 semen specimens from 19 (73%) participants. Median duration of Ebola virus RNA detection was 158 days after onset (73–181; maximum 407 days at end of follow-up). Mathematical modelling of the quantitative time-series data showed a mean clearance rate of Ebola virus RNA from seminal fluid of −0·58 log units per month, although the clearance kinetic varied greatly between participants. Using our biostatistical model, we predict that 50% and 90% of male survivors clear Ebola virus RNA from seminal fluid at 115 days (90% prediction interval 72–160) and 294 days (212–399) after disease onset, respectively. We also predicted that the number of men positive for Ebola virus RNA in affected countries would decrease from about 50 in January 2016, to fewer than 1 person by July, 2016. Infectious virus was detected in 15 of 26 (58%) specimens tested in mice.InterpretationTime to clearance of Ebola virus RNA from seminal fluid varies greatly between individuals and could be more than 13 months. Our predictions will assist in decision-making about surveillance and preventive measures in EVD outbreaks.FundingThis study was funded by European Union's Horizon 2020 research and innovation programme, Directorate-General for International Cooperation and Development of the European Commission, Institut national de la santé et de la recherche médicale (INSERM), German Research Foundation (DFG), and Innovative Medicines Initiative 2 Joint Undertaking.